In contrast, serum DKK1 was also reported to be significantly lower in cancers, such as in multiple myeloma responding to anti-myeloma treatment [22], clear cell renal cell carcinoma [23] and so on. This evidence concerns the gene DKK1 and plasma cell myeloma.